Secondary Brain Mets Prevention after T-DM1 in patients with HER2+ Breast Cancer (BRIDGET) - Clinical Trial

Who Can Participate in the Study?

Age Group

Study Details

Full Title
Secondary BRain metastases prevention after Isolatedintracranial progression on Trastuzumab/Pertuzumab or T-DM1 in patients with aDvanced human epidermal Growth factor receptor 2+ brEast cancer with the addition of Tucatinib (BRIDGET)
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00109777
NCT: NCT05323955
Phase II
Enrollment Status
Open for Enrollment